Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program



Status:Recruiting
Conditions:Psychiatric, Gastrointestinal
Therapuetic Areas:Gastroenterology, Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:2/9/2019
Start Date:April 2014
End Date:October 2020

Use our guide to learn which trials are right for you!

The purpose of this study is to determine the effect that an educational intervention has on
patient knowledge of the signs of opioid overdose and appropriate use of naloxone in a
suburban outpatient treatment program.

The outpatient Addiction Services program at Linden Oaks will begin implementing an
educational program on the signs of opioid overdose and naloxone for all patients who have a
diagnosis of opiate dependence in the investigators suburban treatment program. Subjects will
be recruited from that population and administered a new, empirically validated scale (i.e.
the Opiate Overdose Knowledge Scale; OOKS) both pre- and post-intervention to measure the
effect that the educational program has on patient knowledge.

Patients will also be surveyed (i.e. History Survey) about their experiences over the
previous 12-months (e.g. exposure to opiate overdoses, access/use of naloxone) prior to
treatment; and, this History Survey will then be re-administered by phone, 1-3 months after
discharge. The aim is to measure whether education influences patient behavior. Finally, all
subjects will be administered an empirically-validated measure to assess subject shame and
guilt (i.e. Guilt and Shame Proneness Scale; GASP), and response patterns in their behavior,
to evaluate whether shame and guilt predict behavior at follow-up. The investigators will
compare to data (i.e. OOKS, GASP, and History Survey) from a historical control group prior
to the implementation of the educational program - and, also at 1-3 month follow-up.

Inclusion Criteria:

- Adult subjects who have been diagnosed with a DSM opioid use disorder by LOH staff.

Exclusion Criteria:

- Subjects who are deemed to have moderate to severe cognitive impairment - as assessed
by standard psychiatric evaluation from Linden Oaks clinical staff - will be excluded
from the study.
We found this trial at
1
site
Naperville, Illinois 60563
Principal Investigator: David C Lott, M.D.
Phone: 630-305-5108
?
mi
from
Naperville, IL
Click here to add this to my saved trials